Schizophrenia remains one of the most complex and challenging mental health conditions to diagnose early and accurately. Traditional methods often result in late detection and misdiagnosis, delaying access to proper treatment and support. VOLABIOS addresses this gap by introducing a revolutionary, non-invasive approach to early schizophrenia (SZ) detection.

VOLABIOS project brings together advanced portable spectrometry, multi-omics analysis, and VOC biomarker validation to create a comprehensive diagnostic framework. By focusing on early-stage identification — even before symptoms fully emerge — VOLABIOS enables faster diagnosis, reduces clinical uncertainty, and supports better patient outcomes.

Using real-time Ion Mass Spectrometry (IMS) and innovative digital tools, VOLABIOS delivers accessible, low-cost diagnostic solutions that are validated through extensive clinical studies involving over 3,600 participants across Europe. At its core, the project combines cutting-edge science with co-design and citizen engagement to ensure its tools are practical, ethical, and ready for real-world healthcare systems.

VOLABIOS is not just about technology — it’s about transforming mental healthcare, starting with how we detect and understand schizophrenia.

Explore our glossary page for clear explanations of all key terms used in VOLABIOS.